Micellar paclitaxel in the treatment of patients with tumors of the female reproductive system
Background. Treatment of patients with advanced cancers of the female reproductive system is very challenging. The most common treatment scheme for such patients includes paclitaxel 135—175 mg/m2 + carboplatin AUC 5—6 or cisplatin 75 mg/m2. However, lengthy treatment with this regimen is limited by...
Saved in:
Main Authors: | A. G. Kedrova, S. E. Krasilnikov, D. A. Astakhov, V. V. Kosyy |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2019-11-01
|
Series: | Опухоли женской репродуктивной системы |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/661 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PENURUNAN NILAI HANTARAN TULANG PADA PENDERITA KARSINOMA NASOFARING DENGAN KEMOTERAPI BERBASIS PLATINUM: KOMBINASI NEOADJUVANT PACLITAXEL-CISPLATIN DAN PACLITAXEL-CARBOPLATIN
by: Cika Apriliana, et al.
Published: (2019-02-01) -
Bavachin enhances paclitaxel sensitivity in ovarian cancer cells through modulation of mitochondrial function and ER stress
by: Sang-Jin Lee, et al.
Published: (2025-12-01) -
Synthesis and Characterization of Poly(Lactic-Co-Glycolic Acid)–Paclitaxel (PLGA-PTX) Nanoparticles Evaluated in Ovarian Cancer Models
by: Sylwia A. Dragulska, et al.
Published: (2025-05-01) -
The first experience with intraabdominal chemotherapy in patients with disseminated ovarian cancer
by: A. S. Tyulyandina, et al.
Published: (2014-08-01) -
Nanoparticle albumin-bound paclitaxel – first step of nanotechnology into clinical practice
by: R. N. Alyautdin, et al.
Published: (2022-06-01)